CARDINAL HEALTH INC Q1 FY2027 earnings call

• Strategic Renewals & Stability: Secured the renewal of CVS Health through June 2032 and renewed contracts representing nearly two-thirds of enterprise revenue over the last 12 months, providing a stable foundation for investment.
• Pharma Execution: Delivered strong demand across specialty (high teens growth) and generics. The Solaris acquisition integration is on track with results meeting business case expectations. Specialty Alliance MSO strategy continues to build connected platforms for community physicians.
• Biopharma Solutions Expansion: Expanding 3PL and cold chain capacity via a new St. Louis facility expected to operate by end of calendar year 2027. Synexis Patient Hub is growing organically, on track to double therapies supported by fiscal 28.
• GMPD Improvement Plan: Executing operational improvements including deploying over 100 autonomous robots at the Dixon, CA distribution center. Cardinal Health brand specialty portfolio grew above market rates.
• Growth Businesses Momentum: At-home solutions successfully migrated Stride Medical into the nationwide network and began construction on a new Sacramento Distribution Center. Nuclear and Precision Health saw strong momentum in PET and theranostics, with AI-driven route optimization rolling out to radiopharmacies. Optifreight Logistics enhanced pharmacy solution tracking visibility.

Pharma: Revenue increased 6% to $62.6 billion; segment profit rose 17% to $783 million. Pharma represents approximately 92.8% of total company revenue ($62.6B / $67.5B). Global Medical Products and Distribution (GMPD): Revenue was roughly flat at $3.2 billion; segment profit was $33 million. GMPD represents approximately 4.7% of total company revenue. Other (Growth Businesses): Revenue grew 7% to $1.8 billion; profit increased 16% to $193 million. 'Other' represents approximately 2.7% of total company revenue.

• Full-Year EPS: Raised non-GAAP diluted EPS guidance to $12.80–$13.00 from $12.40–$12.60.
• Pharma Segment: Maintained revenue growth guidance of 3–5%. Increased segment profit growth guidance to 10–12% from 8–11%.
• GMPD Segment: Maintained revenue growth guidance of 2–4%. Maintained profit guidance of $200–$220 million, though noted that high petroleum costs may push results toward the low end.
• Other Segment: Raised revenue growth guidance to 12–14% from 11–13%. Raised profit growth guidance to 17–20% from 15–18%.
• Below-the-Line Items: Interest and other expenses expected between $240–$290 million. Effective tax rate lowered to 18.5–19.5% from 19–20%.
• Capital Allocation: CapEx remains ~$700 million. Diluted shares outstanding expected at 231–232 million. Adjusted free cash flow expected between $3.5–$4.0 billion.

• Regulatory Uncertainty: Potential impacts from OPPS rule finalization and 340B reimbursement changes, though management believes intent is not to harm community providers and expects to pick up volume shifts.
• Macroeconomic Factors: Global volatility, foreign exchange headwinds, and sustained high petroleum costs impacting GMPD profitability.
• Operational Integration: Risks associated with integrating acquisitions like Solaris and Stride Medical, requiring careful execution to maintain physician experience and realize synergies.
• Political/Policy Environment: Ongoing election-related policy changes, though management views these as manageable due to constructive engagement and essential role in healthcare.

Q: Morgan Stanley asked about underlying momentum in pharma distribution excluding renewals/Solaris, specifically regarding generics and specialty trends.

A: CFO Aaron Alt highlighted strong unit demand in specialty (urology/oncology) and resilient Red Oak generics performance. He noted Solaris lapping in Q2 and CVS renewal impacts are baked into guidance, but underlying demand assumptions remain robust for the rest of the year.

Q: Evercore ISI sought details on the 'Other' segment's strength, asking if it stems from early deal synergies or uniform customer acceptance across At-Home, Nuclear, and OptiFreight.

A: Alt confirmed secular tailwinds drive growth, with At-Home realizing ADSG/Stride synergies, Nuclear expanding PET/theranostics capacity, and OptiFreight gaining new customers. He emphasized that growth will accelerate in H2, driven by pipeline confidence and integration benefits.

Q: Leerink Partners asked how the combination of distribution, MSOs, and other capabilities creates a '1+1+1>3' dynamic, using urology as an example.

A: CEO Jason Hollar described a virtuous cycle where specialized therapeutic areas connect various business units. For urology, this links pharma distribution, Solaris MSO support, At-Home delivery, and Nuclear radiopharmaceuticals, allowing cross-selling and shared expertise rather than relying on single home-run drivers.

Q: Deutsche Bank asked how the finalized OPPS rule and 340B reimbursement changes impact provider dynamics and whether volume might shift to Cardinal Health’s MSOs.

A: Hollar stated that while health systems must navigate affordability, he anticipates patients moving to alternative care sites consistent with Cardinal Health’s fair share of market. He views this as a logical outcome but considers it premature to quantify specific volume shifts.

Q: UBS asked about future M&A focus, questioning if the firm will pursue clinical trial opportunities or follow competitors like McKesson, or stay focused on existing legs.

A: Hollar clarified that M&A will strictly align with the current three strategic pillars (Pharma, Specialty, Other Growth), avoiding a 'fourth leg.' He highlighted fragmentation in MSOs, Biopharma Solutions (3PL/Synexis), and At-Home as key areas for consolidation and partnership, leveraging strong free cash flow for targeted deals.